Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating
chronic graft-versus-host disease. It is not yet known if standard therapy for
graft-versus-host disease is more effective with or without hydroxychloroquine.
PURPOSE: Randomized phase III trial to compare the effectiveness of standard therapy alone
with that of standard therapy plus hydroxychloroquine in treating patients who have newly
diagnosed chronic graft-versus-host disease.